Weekly injection could tame bleeding in kids with Hard-to-Treat ITP
NCT ID NCT07214025
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called romiplostim, given as a weekly shot, in 100 children aged 1 to 18 with chronic immune thrombocytopenia (ITP) who haven't been helped by standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding. Children will be monitored for nearly a year to check how well the drug works and if it causes any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romiplostim (a once-weekly injection that stimulates platelet production)
What this could lead to
If it works, this could offer a new, effective option to control bleeding and maintain safe platelet levels in children with chronic ITP who haven't responded to standard treatments.
What could go wrong
This is an early-stage study with only 100 children, so results may not apply to everyone. The drug requires ongoing injections and may cause side effects like bone pain or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROMIPLOSTIM N01 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••